Age: 63.0
Sex: F
Vaccine: FLU4, VARZOS
Symptoms: Condition aggravated, Pityriasis, Pityriasis rosea
Clinical narrative: Pityriasis rosea; This spontaneous case was received on 28-Oct-2020 with additional information (being processed together) received on 29-Oct-2020 from physician via Med Communications (reference number: SEQW20-04410) and concerned a 63-year-old female patient.  The patient's concurrent conditions included low vitamin D and rash. The patient's historical vaccines included Afluria Quadrivalent (influenza vaccine) in 2019, after which the patient was diagnosed with pityriasis. The patient was not taking any concomitant medications.  On 15-Oct-2020, the patient was vaccinated with Afluria Quadrivalent (influenza vaccine, dose: 0.5 ml, anatomical location: right deltoid, route of administration: not reported) for influenza prophylaxis. The batch number reported was P100251770, expiration date: 30-Jun-2021.  On the same day, the patient was vaccinated with non-company co-suspect Shingrix vaccine (varicella zoster vaccine rge (cho); dose, route of administration, anatomical location and indication: not reported). The batch number was not reported.  On 19-Oct-2020, four days after vaccination, the patient developed rash. The patient did not receive any treatment.  On an unknown date in 2020, the patient went to her dermatologist and after biopsy, she was diagnosed with pityriasis rosea.  At the time of initial reporting on 28-Oct-2020, the patient had not recovered from the event.  The reporter did not provide a causality assessment.  This case is linked to the cases 202005898 and 202005897 (the same patient).   Additional information received on 03-Dec-2020 from physician, with additional information (being processed together) on 07-Dec-2020: Historical vaccine from 2018 removed, as it was confirmed that the rash was a month before receiving the flu vaccine. Rash was added as historical condition, Lab data updated with biopsy. Event of rash recoded to pityriasis rosea, since diagnose from dermatologist was provided. Narrative was amended accordingly.  Company comment: A 63-year-old female patient experienced pityriasis rosea 4 days after administration of Afluria Quadrivalent and a non-company co-suspect Shingrix vaccine. The event was confirmed after biopsy and consultation with dermatologist. The patient's concurrent conditions included low vitamin D and rash, while historical vaccines included Afluria Quadrivalent (influenza vaccine) in 2019, after which the patient was diagnosed with pityriasis. The patient was not taking any concomitant medications. Causality is assessed as possibly related having in mind presented information.; Sender's Comments: A 63-year-old female patient experienced pityriasis rosea 4 days after administration of Afluria Quadrivalent and a non-company co-suspect Shingrix vaccine. The event was confirmed after biopsy and consultation with dermatologist. The patient's concurrent conditions included low vitamin D and rash, while historical vaccines included Afluria Quadrivalent (influenza vaccine) in 2019, after which the patient was diagnosed with pityriasis. The patient was not taking any concomitant medications. Causality is assessed as possibly related having in mind presented information.